Treatment of alzheimer's disease

Details Treatment of alzheimer's disease Treatment of alzheimer's disease

2003-09-04

2009-12-01

Nickol, Gary B (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C530S351000, C435S020000

Reexamination Certificate

active

07625554

ABSTRACT:
The present invention provides a method for treating cognitive decline in a patient by administering to the patient at least about 100 units per day of α-interferon.

REFERENCES:
Brod SA, Kermoan RH, Nelson LD, Marshall GD, Henninger EM, Khan M, Jin R, Wolinsky JS. Ingensted IFN-alpha has biological efects in humans with relapsing-remitting multiple sclerosis. Mult Scler. Feb. 1997; 3(1):1-7.
Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, Noviasky J. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Pschopharmacol. Jun. 2000; 20(3):350-6.
Kujala P, Portin R, Ruutiainen J. The Progress of cognitive decline in multiple sclerosis. Brain. 1997. 120:289-297.
Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry. Sep. 1996; 61(3):324-5.
Steinman L, et al. Multiple sclerosis: Deeper understanding of its pathogenesis reveals new targets for therapy. 2002, Ann. Rev. Neurosci. vol. 25, p. 491-505.
Brod S.A. Unregulated inflammation shortens human functional longevity. Inflammation Research. 2000. vol. 49, pp. 561-570.

Affiliated with

Also associated with

Rating

Treatment of alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of alzheimer's disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4070688